BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 30, 2004
View Archived Issues
Phase I data on the effects and safety of pemetrexed in breast cancer
Read More
New developments at Theratechnologies
Read More
BioMarin begins phase II trial of Phenoptin for PKU
Read More
U.S. phase IIb results for Technosphere Insulin, phase III begins in Europe
Read More
Cerus acquires mesothelin license from Chugai
Read More
Matritech refines NMP66 detection for breast cancer
Read More
Canadian approval for Cipralex
Read More
Centocor licenses rights to ImmunoGen's TAP technology
Read More
Vfend approved for candidemia in nonneutropenic patients
Read More
NDA submission for premature ejaculation treatment dapoxetine hydrochloride
Read More
Myriad Genetics files to begin phase I trial with MPC-2130
Read More
Treatment completed in phase III phenserine trial
Read More
Tipifarnib shows promise in the treatment of breast cancer
Read More
Phase II data on the effects of ZD-6474 in metastatic breast cancer
Read More
Ventavis approved for PAH
Read More
Update on the cognitive effects and safety profile of TC-1734
Read More
Contrast agents claimed by Fuji Photo Film
Read More
PTC develops compounds for diseases related to nonsense mutations of mRNA
Read More
Antitumor agents reported in patent literature
Read More
Yamanouchi team presents series of novel anticoagulants
Read More
IgG1 monoclonal antibodies for cancer therapy prepared and tested at Crucell
Read More
Finasteride tested to treat alcoholism
Read More
Clolar approved for pediatric ALL
Read More
Prialt receives FDA approval for severe chronic pain
Read More
Synthesis and preclinical efficacy of YM-75440, a novel, orally active squalene synthase inhibitor
Read More
Novel derivative of curcumin induces cell cycle arrest of HCT15 colon cancer cells
Read More
COX-2-derived prostacyclin is atheroprotective in female mice
Read More